Study of patients who started taking blockbuster weight loss drugs in 2021 suggests patients need support services, not just ...

After insurance for New York City employees began covering GLP-1 weight-loss injectables, more than 1,000 city workers and ...

News and talk of GLP-1 drugs are everywhere these days—from their smash success in treating Type 2 diabetes and obesity to ...

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim ...

The findings spell an uncertain future for hospitals and clinics that derive a significant portion of their revenues from ...

A new study by researchers at Brigham and Women's Hospital in collaboration with researchers at Harvard T.H. Chan School of ...

The demand for bariatric operations dropped sharply last year as use of anti-obesity drugs such as Wegovy surged, study finds ...

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates ...

Companies are figuring out how to cater to consumers using GLP-1 drugs, such as Ozempic.

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim ...

Moving ahead, Rob Rowe, Regional Research Director and Head of Global Strategy at a large US bank is ‘ tactically bullish ’ on the back of continuing tech recovery and the markets “pricing in a soft ...

ResMed stock broke out early Friday after the CPAP maker broadly beat third-quarter projections.Please watch the video at Investors.com - S&P 500 Giants Report Earnings. Will Megacap Results Sustain ...